A trial of autologous ex vivo- expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: Phase IIa study

Anticancer Research

Volumn 33, Issue 5, 2013, Pages 2115-2122

  Yang, Young Jun ^a   Park, Ji Chan ^a   Kim, Hoon Kyo ^b   Kang, Jin Hyoung ^c   Park, Suk Young ^a  

^a Daejeon St Mary's Hospital   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

Docetaxel; MICA B; NK cell enriched lymphocytes (NKL); NKG2D; NSCLC; Phase II study

Indexed keywords

DEXAMETHASONE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; NATURAL KILLER CELL RECEPTOR NKG2D;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; EX VIVO STUDY; FEMALE; HISTOCOMPATIBILITY COMPLEX; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; LUNG NON SMALL CELL CANCER; MALE; MULTIMODALITY CANCER THERAPY; NATURAL KILLER T CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; TREATMENT REFUSAL; UNSPECIFIED SIDE EFFECT;

DOCETAXEL; MICA/B; NK CELL-ENRICHED LYMPHOCYTES (NKL); NKG2D; NSCLC; PHASE II STUDY;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KILLER CELLS, NATURAL; LUNG NEOPLASMS; LYMPHOCYTES; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TAXOIDS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84878188324     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Salgia R, Hensing T, Campbell N, Salama AK, Maitland M, Hoffman P, Villaflor V and Vokes EE: Personalized treatment of lung cancer. Semin Oncol 38(2): 274-283, 2011.
2. Kim JY, Son YO, Park SW, Bae JH, Chung JS, Kim HH, Chung BS, Kim SH and Kang CD: Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation. Exp Mol Med 38(5): 474-484, 2006.
3. Mistry AR and O'Callaghan CA: Regulation of ligands for the activating receptor NKG2D. Immunology 121(4): 439-447, 2007. (Pubitemid 47030096)
4. Zitvogel L, Apetoh L, Ghiringhelli F and Kroemer G: Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8(1): 59-73, 2008.
5. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E and Vetto JT: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313(23): 1485-1492, 1985. (Pubitemid 16212345)
6. Arina A, Murillo O, Dubrot J, Azpilikueta A, Alfaro C, Pérez-Gracia JL, Bendandi M, Palencia B, Hervás-Stubbs A and Melero I: Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer. Expert Opin Biol Ther 7(5): 599-615, 2007. (Pubitemid 46707184)
7. Jun Wu and Lanier LL: Natural killer cells and cancer. Adv Cancer Res 90: 127-156, 2003.
8. Berg M, Lundqvist A, McCoy P Jr., Samsel L, Fan Y, Tawab A and Childs R: Clinical-grade ex vivo -expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy. 11(3): 341-355, 2009.
9. Morisaki T, Onishi H, Koya N, Kiyota A, Tanaka H, Umebayashi M, Ogino T, Nagamatsu I and Katano M: Combinatorial cytotoxicity of gemcitabine and cytokine-activated killer cells in hepatocellular carcinoma via the NKG2D-MICA/B system. Anticancer Res 31 (7): 2505-2510, 2011.
10. Brookmeyer R and Crowley J: A confidence interval for the median survival time. Biometrics 38: 29-41, 1982.
11. Bria E, Cuppone F, Ciccarese M, Nisticò C, Facciolo F, Milella M, Izzo F, Terzoli E, Cognetti F and Giannarelli D: Weekly docetaxel as second-line chemotherapy for advanced non-small cell lung cancer: Meta-analysis of randomized trials. Cancer Treat Rev 32(8): 583-587, 2006. (Pubitemid 44645022)
12. Eisenhauera EA, Therasse P, Bogaertsc J, Schwartzd LH, Sargente D, Fordf R, Danceyg J, Arbuckh S, Gwytheri S, Mooneyg M, Rubinsteing L, Shankarg L, Doddg L, Kaplanj R, Lacombec D and Verweijk J: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
13. Farag SS, Fehniger TA, Ruggeri L, Velardi A and Caligiuri MA: Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 100(6): 1935-1947, 2002. (Pubitemid 35001221)
14. Rajalingam R. Human diversity of killer cell immunoglobulin-like receptors and disease. Korean J Hematol 46 (4): 216-228, 2011.
15. Textor S, Dürst M, Jansen L, Accardi R, Tommasino M, Trunk MJ, Porgador A, Watzl C, Gissmann L and Cerwenka A: Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int J Cancer 123 (10): 2343-2353, 2008.
16. Xu X, Rao G, Gaffud MJ, Ding HG, Maki G, Klingemann HG, Groh V, Spies T, Caillat-Zucman S, Gattuso P, Plate J and Prinz RA: Clinicopathological significance of major histocompatibility complex class I-related chain A and B expression in thyroid cancer. J Clin Endocrinol Metab 91(7): 2704-2712, 2006. (Pubitemid 44024641)
17. Gasser S, Orsulic S, Brown EJ and Raulet DH: The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436: 1186-1190, 2005. (Pubitemid 41232299)
18. Stern-Ginossar N and Mandelboim O: An integrated view of the regulation of NKG2D ligands. Immunology 128(1): 1-6, 2009.
19. Zhang C, Wang Y, Zhou Z, Zhang J and Tian ZP: Sodium butyrate up-regulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis. Cancer Immunol Immunother 58(8): 1275-1285, 2009.
20. Ma Y, Conforti R, Aymeric L, Locher C, Kepp O, Kroemer G and Zitvogel L: How to improve the immunogenicity of chemotherapy and radiotherapy. Cancer Metastasis Rev 30(1): 71-82, 2011.